Interstitial lung diseases (ILDs) are a group of disorders that can cause lung scarring, reducing oxygen transfer and making breathing difficult. The interstitium becomes thick and stiff, impairing gas exchange and progressively affecting respiratory function.
FDA approves AstraZeneca and Daiichi Sankyo's Datroway for first-line TNBC patients not eligible for PD-1/L1 inhibitors, based on Phase III TROPION-Breast02 data showing a 21% reduction in risk of death versus chemotherapy.
The FDA has approved Lifyorli (relacorilant) plus nab-paclitaxel for platinum-resistant ovarian cancer based on trial data showing improved survival. Separately, the agency granted Breakthrough Therapy designation to Lilly's sofetabart mipitecan for the same condition, expediting development of the antibody-drug conjugate.
Trastuzumab deruxtecan is moving into earlier treatment lines for HER2-positive metastatic breast cancer, demonstrating superior efficacy over standard regimens and prompting reconsideration of long-standing treatment sequences.
The FDA has expanded approval of GSK's Arexvy RSV vaccine to include adults aged 18 to 49 years at increased risk for lower respiratory tract disease, based on phase 3b trial data showing noninferior immune response.
AIM ImmunoTech partners with Thermo Fisher to design Phase 3 trial for Ampligen in pancreatic cancer, while Innovent Biologics begins dosing patients in Phase 3 study of IBI354 for HER2-positive breast cancer.
Insmed reported total revenues of $606.4 million for 2025, with ARIKAYCE growing 19% annually. The FDA granted orphan drug designation to treprostinil palmitil for pulmonary arterial hypertension treatment in January 2026.
A 24-year-old woman with refractory lupus achieved two successful pregnancies following dual-target CAR-T cell therapy, while bispecific T cell engagers showed efficacy in treatment-refractory antisynthetase syndrome and systemic sclerosis patients.
Eli Lilly's Retevmo (selpercatinib) demonstrated statistically significant event-free survival improvement in the Phase III LIBRETTO-432 trial for early-stage RET fusion-positive non-small cell lung cancer.
Eli Lilly's Retevmo demonstrated statistically significant improvement in event-free survival versus placebo in stage II-IIIA RET fusion-positive non-small cell lung cancer following curative therapy in the phase 3 LIBRETTO-432 trial.
Innovent Biologics has dosed the first participant in its pivotal Phase 3 HeriCare-Breast01 study evaluating IBI354, a HER2-targeted antibody-drug conjugate, as first-line treatment for unresectable locally advanced or metastatic HER2-positive breast cancer.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07572383 |
Advanced Imaging to Assess the Effect of Immunosuppression on Progressive Fibrosis |
RECRUITING | PHASE2 |
| NCT07561034 |
The Benefits of Home Exercise in Pulmonary Hypertension Interstitial Lung Disease |
NOT_YET_RECRUITING | NA |
| NCT07541638 |
Early Recognition of Progressive Lung Fibrosis in Systemic Rheumatic Diseases |
RECRUITING | NA |
| NCT07512687 |
Titrated Ambulatory Oxygen in Fibrotic ILD and COPD With Isolated Exertional Hypoxemia |
NOT_YET_RECRUITING | NA |
| NCT07493187 |
Magnetic Resonance Imaging of the Lung: Non-Oncological Applications |
RECRUITING | |
| NCT07486869 |
Emapalumab MDA5 Rapidly Progressive Interstitial Lung Disease (RP-ILD) Study |
NOT_YET_RECRUITING | PHASE2 |
| NCT07459179 |
Clinical Study on the Application of PET Probes Targeting DDR2 in the Diagnosis of Interstitial Lung Disease With Cognitive Impairment |
NOT_YET_RECRUITING | |
| NCT07451977 |
Effects of Oxygen Supplementation During the 6-Minute Walk Test in Chronic Respiratory Failure or Exertional Hypoxemia |
RECRUITING | NA |
| NCT07443436 |
Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants |
NOT_YET_RECRUITING | PHASE2 |
| NCT07323732 |
A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Disease |
RECRUITING | PHASE2 |
